Because ERRα belongs to a class of druggable NRs, our in vitro and in vivo studies suggest that the ERRα antagonist XCT790 might be considered as a potential drug to treat colon cancer patients with defective p53 status. The gene discussed is TP53; the disease is colonic neoplasm.